Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana
With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
Sonowal exhorted young researchers and scientist to work on evidence based scientific research
This order is subject to initial advance payment as per the agreed terms of the contract
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Subscribe To Our Newsletter & Stay Updated